A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity

Abstract Background Agonistic monoclonal antibodies targeting 4-1BB/CD137 have shown preclinical promise, but their clinical development has been limited by severe liver toxicity or limited efficacy. Therefore, a safe and efficient immunostimulatory molecule is urgently needed for cancer immunothera...

詳細記述

書誌詳細

出版年:	Journal of Translational Medicine
主要な著者:	Da-yan Zhang, Zhi-hua Zhang, Wen-ting Liu, Wei-ming Zhou, Peng-fei Zhou, Juan-juan Wei, Xue-jing Dai, Xiao-li Zeng, Yu-qiong Zhou, Han-wang Li, Heng Zhang, Ao-lin Shen, Lian-sheng Cheng, Guo-dong Shen, Yi-fu He
フォーマット:	論文
言語:	英語
出版事項:	BMC 2025-01-01
主題:	4-1BB/CD137 MSLN Bispecific antibody Cancer immunotherapy Antitumour immunity
オンライン･アクセス:	https://doi.org/10.1186/s12967-025-06107-z